omvitrastat + darolutamide

OP-3136 + darolutamide is an investigational combination therapy consisting of omvitrastat (OP-3136), an oral small-molecule inhibitor of lysine acetyltransferase 6A/B (KAT6A/B), and darolutamide (Nubeqa), an oral androgen receptor inhibitor. Developed under a clinical trial collaboration between Olema Oncology and Bayer, this combination is designed to treat metastatic castration-resistant prostate cancer (mCRPC). By combining the epigenetic modulation of KAT6 inhibition with the hormonal blockade of androgen receptor antagonism, the therapy aims to overcome resistance mechanisms and improve clinical outcomes in patients with advanced prostate cancer. A Phase 1b/2 clinical trial is planned to evaluate the safety, tolerability, and preliminary efficacy of this combination.